AtaGenix Excels at Thailand LAB International 2025: Pioneering Antibody Discovery & Protein Expression

Bangkok, September 8, 2025 — AtaGenix Laboratories Co., Ltd. made a remarkable appearance at Thailand LAB International 2025, held from September 3-5, 2025, at the Bangkok International Trade & Exhibition Centre (BITEC), booth 2S21. As Southeast Asia’s premier exhibition for laboratory technology and life sciences, the event attracted over 9,000 professionals from more than 60 countries and 270 leading companies, serving as a vital platform for global scientific and industrial collaboration.

Fig.1. AtaGenix Team Engaging with Clients at the Booth

During the event, AtaGenix showcased its cutting-edge achievements in antibody discovery and optimization, nanobody development, protein expression and purification, antibody engineering, and the abinScience product portfolio. The company’s core team engaged in in-depth discussions with researchers, industry experts, and potential partners from around the world, highlighting AtaGenix’s leadership in the global biotechnology sector.

Event Background

Thailand LAB International 2025, now in its 15th year, is Asia’s leading exhibition for laboratory technology, life sciences, biotechnology, and chemical innovation. Held alongside BioAP INTERNATIONAL, FutureCHEM INTERNATIONAL, and Health & Innovation Asia, the event covered areas such as analytical testing, clinical diagnostics, biotechnology, and environmental safety. Featuring laboratory equipment, analytical technologies, biopharmaceuticals, and health innovations, the exhibition offered 65 high-level seminars, insights from 160 global experts, and targeted business matching, fostering collaboration among industry leaders, research institutions, and enterprises to drive scientific advancement in the Asia-Pacific region.

Fig.2. AtaGenix Team Presenting at the Technical Seminar

Event Highlights

AtaGenix’s booth (2S21) was a focal point of the exhibition, featuring its robust five-protein expression systems, hybridoma and phage display antibody discovery platforms, and core technologies for antibody drug discovery, including nanobody development, phage display antibody library construction, antibody screening, hybridoma sequencing, Xten™ Mab Single B rabbit monoclonal antibody development, antibody humanization, and high-throughput low-endotoxin recombinant antibody expression and purification. These technologies addressed diverse research needs while providing strong support for in vitro diagnostics (IVD) and drug development.

The AtaGenix team conducted extensive business discussions with representatives from pharmaceutical, diagnostic, and research institutions, successfully establishing multiple potential partnerships. During the event, the company participated in several technical seminars, sharing the latest advancements in antibody engineering and protein expression, which received widespread acclaim. Additionally, the abinScience product portfolio garnered significant attention for its high performance and innovation, solidifying AtaGenix’s foundation for further expansion in the Asia-Pacific market.

Fig.3. Industry Partners Visiting AtaGenix Booth

Contact Us
AtaGenix Laboratories Co., Ltd.
Address: Building C, No. 666 Shendun 4th Road, East Lake New Technology Development Zone, Wuhan, China
Phone: +86-27-87001869
Email: info@atagenix.com
Website: www.atagenix.com